|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
|
|---|---|---|
| Revenue | ||
| Screening revenue | ||
| Development Services | ||
| Total revenue | ||
| Costs and operating expenses | ||
| Cost of revenue | ||
| Screening revenue | ||
| Development Services | ||
| Cost of revenue — amortization of intangible assets | ||
| Research and development | ||
| Sales and marketing | ||
| General and administrative | ||
| Goodwill and intangible assets impairment | ||
| Total costs and operating expenses | ||
| Loss from operations | ||
| Other income | ||
| Interest income | ||
| Other income (expense), net | ||
| Total other income, net | ||
| Loss before income taxes | ||
| Benefit from income taxes | ||
| Net loss | ||
| Net loss per share | ||
| Net loss per share— Basic (in dollars per share) | ||
| Net loss per share—Diluted (in dollars per share) | ||
| Weighted-average shares of common stock used in computing net loss per share—basic (in shares) | ||
| Weighted-average shares of common stock used in computing net loss per share—diluted (in shares) |
Loading...
